

STANDARD TREATMENT WORKFLOW (STW)

Cutaneous Adverse Drug Reactions - B

Binod K Khaitan¹, Deepika Pandhi², Ananta Khurana³, Dipankar De⁴, Rahul Mahajan⁵, Renu George⁶, Vishal Gupta⁷

¹All India Institute of Medical Sciences, New Delhi; ²University College of Medical Sciences, New Delhi; ³Dr. Ram Manohar Lohia Hospital, New Delhi; ⁴Postgraduate Institute of Medical Education and Research, Chandigarh; ⁵Postgraduate Institute of Medical Education and Research, Chandigarh; ⁶ Christian Medical College, Vellore; ⁷All India Institute of Medical Sciences, New Delhi

CORRESPONDING AUTHOR

Dr Binod K Khaitan, Department of Dermatology, All India Institute of Medical Sciences, New Delhi
Email: binodkhaitan@hotmail.com

CITATION

Khaitan BK, Pandhi D, Khurana A, De D, Mahajan R, George R, Gupta V. Cutaneous Adverse Drug Reactions - B. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S85-S86.

DOI: <https://doi.org/10.56450/JEFI.2024.v2i1Suppl.043>

This work is licensed under a Creative Commons Attribution 4.0 International License.

@The Author(s). 2024 Open Access

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.

July/ 2024



Department of Health Research
Ministry of Health and Family Welfare, Government of India



Standard Treatment Workflow (STW)

CUTANEOUS ADVERSE DRUG REACTIONS- PART B

ICD-10-L27.0

Cutaneous adverse drug reactions (cADR) are undesirable clinical manifestations to a drug, which include predictable or unanticipated side effects, with or without systemic involvement.

COMMON TYPES OF cADR

NON- SEVERE cADR

Fixed drug eruption (FDE)*

Maculopapular/ Exanthematous reactions*

Drug induced hypersensitivity syndrome/ DRESS

Acute generalized exanthematous pustulosis

SEVERE cADR

Angioedema/ Anaphylaxis*

Erythema multiforme/ Stevens Johnson syndrome/ Toxic epidermal necrolysis

*Refer to separate STW on Urticaria/ Angioedema, and cADR Part-A for FDE/ Maculopapular/ Exanthematous reactions

DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) SYNDROME

- Potentially life threatening systemic adverse reaction
- Onset 2-6 weeks after start of drug intake (up to 12 weeks)
- The rash may continue to progress weeks to months after discontinuation of the drug
- Commonly observed with anticonvulsants, dapsone, allopurinol, abacavir, leflunomide, minocycline

When to suspect DRESS syndrome

- Exposure to a high risk drug
- Clinical presentation: fever (>38°C-40°C), rash, leukocytosis with eosinophilia, lymphadenopathy, hepato-renal dysfunction
- Features of the rash: involves >50% body surface area, facial edema, desquamation or dusky erythema
- Occasionally pustules and targetoid lesions may be seen

MANAGEMENT

PRIMARY CARE

- Withdraw drugs
- Assess vitals, stabilise the

SECONDARY CARE

- Same as primary care
- CBC, absolute eosinophil count (optional), LFT, renal function-monitored at least weekly


TERTIARY CARE

- Same as primary/ secondary care
- Second line - Cyclosporine (if the renal function is normal)

Standard Treatment Workflow (STW)
CUTANEOUS ADVERSE DRUG REACTIONS- PART B
ICD-10-L27.0

Cutaneous adverse drug reactions (cADR) are undesirable clinical manifestations to a drug, which include predictable or unanticipated side effects, with or without systemic involvement.

COMMON TYPES OF cADR



*Refer to separate STW on Urticaria/ Angioedema, and cADR Part-A for FDE/ Maculopapular/ Exanthematous reactions

DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) SYNDROME

- Potentially life threatening systemic adverse reaction
 - Onset 2-6 weeks after start of drug intake (up to 12 weeks)
 - The rash may continue to progress weeks to months after discontinuation of the drug
 - Commonly observed with anticonvulsants, dapsone, allopurinol, abacavir, leflunomide, minocycline
- When to suspect DRESS syndrome**
- Exposure to a high risk drug
 - Clinical presentation: fever (>38°C-40°C), rash, leukocytosis with eosinophilia, lymphadenopathy, hepato-renal dysfunction
 - Features of the rash: involves >50% body surface area, facial edema, desquamation or dusky erythema
 - Occasionally pustules and targetoid lesions may be seen

MANAGEMENT

PRIMARY CARE	SECONDARY CARE	TERTIARY CARE
<ul style="list-style-type: none"> Withdraw drugs Assess vitals, stabilise the patient and refer to higher center Symptomatic relief: Antihistamines, emollients Do not add any unnecessary new medications 	<ul style="list-style-type: none"> Same as primary care CBC, absolute eosinophil count (optional), LFT, renal function- monitored at least weekly CXR, ECG and ECHO to rule out myocarditis Treatment If no evidence of major organ involvement First line- Systemic steroids- Prednisolone 0.5-2 mg/kg, slow taper after symptoms and signs resolve (over months if needed) Antihistamines-Pheniramine 25 mg TID, bland emollients like liquid paraffin If there is severe organ involvement- liver, renal or cardiac refer to tertiary center for multidisciplinary intensive care 	<ul style="list-style-type: none"> Same as primary/ secondary care Second line - Cyclosporine (if the renal function is normal) Management will require a multidisciplinary team approach, depending on the organ(s) involved In the presence of severe liver failure, hemophagocytic syndrome, gastrointestinal bleeding, multiorgan failure, the patient may require intensive care treatment

STEVENS JOHNSON SYNDROME (SJS) AND TOXIC EPIDERMAL NECROLYSIS (TEN)

- Acute, severe mucocutaneous reactions associated with epidermal detachment and/ or tenderness, and widespread erythematous lesions with central dusky erythema or vesiculation often associated with high grade fever
- Usually observed with aromatic anticonvulsants, allopurinol, nevirapine, abacavir, NSAIDs, co-trimoxazole
- The classification of SJS, TEN is based on the extent of detachment
- D/d-Staphylococcal scalded skin syndrome, pemphigus

TYPE	DETACHMENT (% BSA)	WIDESPREAD ATYPICAL TARGETS *OR ERYTHEMATOUS MACULES
SJS	<10%	Present
SJS-TEN	10-30%	Present
TEN	≥30%	Present
TEN without SPOTS	≥10%	Absent

*Atypical targets (Red macules with purpuric vesiculations/ crusted centers)

TOXIC EPIDERMAL NECROLYSIS



PROGNOSIS

SCORTEN PROGNOSTIC FACTORS	POINTS
Age > 40 years	1
Tachycardia > 120 bpm	1
Neoplasia	1
Initial detachment > 10%	1
Serum urea > 60 mg/dL	1
Serum bicarbonate < 20mmol/L	1
Blood glucose > 252mg/ dL	1

Assess prognosis with a SCORTEN score done within 24 hours of presentation and repeated 3 days later

SCORTEN SCORE	ESTIMATED MORTALITY %
0-1	3
2	12
3	35
4	58
≥ 5	> 90

INVESTIGATIONS

- Chest X- ray
- ECG
- Laboratory tests-** CBC, LFT, KFT, electrolytes, magnesium, phosphate, lactate
- Blood gas analysis
- Microbiology-** Pus culture from infected areas and blood culture
- Skin biopsy-** Not usually required unless the diagnosis is in doubt
- Optional-** In TEN, biopsy and direct immunofluorescence is useful to rule out SLE and pemphigus

MANAGEMENT

PRIMARY CARE	SECONDARY CARE	TERTIARY CARE
<ul style="list-style-type: none"> See primary care for drug rash with eosinophilia and systemic symptoms (DRESS) 	<ul style="list-style-type: none"> Assess vitals, stabilise the patient, nutrition and fluid replacement as appropriate Local care for skin and mucosae Skin care- dilute potassium permanganate baths/ saline compresses/ Chlorhexidine baths <ul style="list-style-type: none"> Detached epidermis can be left in situ and covered with non-adherent dressing (sterile vaseline gauze) Topical antibiotics (Mupirocin or Fucidin) on sloughed off areas Oral care- Rinse mouth with Chlorhexidine 2-3 times, soft paraffin on lips as needed, steroid mouth washes <ul style="list-style-type: none"> Eye care- refer to ophthalmologist Antibiotics- broad spectrum antibiotics (in case of sepsis or secondary infection) to cover staph, strep and pseudomonas. Change according to culture results and avoid suspected drug class Adjuvant systemic therapy (ideally within the first 24-72 hours of onset) <ul style="list-style-type: none"> The role of systemic steroids is limited to early phase of SJS/TEN. High doses for longer periods can increase the risk of sepsis and metabolic complications. However judicious use of Prednisolone 1-2 mg/kg or equivalent dose of intravenous Dexamethasone for 3-7 days may be of benefit Cyclosporine in a dose of 3-5 mg/kg for a period of 10-14 days (with monitoring) If skin detachment >10% refer to a center with an ICU familiar with management of skin failure If < 10% follow the treatment as described 	<ul style="list-style-type: none"> Admit in specialized units within dermatology wards if vitals are stable and follow secondary care treatment Barrier nursing If patient has SIRS/ sepsis or in shock, admit to ICU Long term follow up will be required to address complications: ophthalmic, skin and respiratory tract involvement

ANY DRUG BELONGING TO ANY MEDICINAL SYSTEM CAN CAUSE cADR

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (stw.icmr.org.in) for more information. ©Department of Health Research, Ministry of Health & Family Welfare, Government of India.